Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ocugen
Biotech
Ocugen update charts course for rivalry with Apellis, Astellas
Ocugen reported phase 2 data on its eye disease gene therapy, providing evidence that the candidate may outperform drugs from Apellis and Astellas.
Nick Paul Taylor
Jan 15, 2026 9:22am
Carisma's lifeline disappears as reverse merger plans break down
Sep 18, 2025 10:40am
Novartis R&D chief Jay Bradner departs—Chutes & Ladders
Sep 2, 2022 9:30am
Ocugen COVID shot will have to wait for US market after FDA hold
Nov 29, 2021 11:27am
Ocugen climbs on phase 3 COVID vaccine data
Jul 6, 2021 9:30am
Ocugen preps dry eye disease drug for phase 3
Mar 20, 2018 10:18am
